Skip to content

About Us
Our Approach
Pipeline
- Overview
- Publications
Clinical Trials
Investors
Contact

About Us
Our Approach
Pipeline
- Overview
- Publications
Clinical Trials
Investors
Contact

PRESS RELEASES

Choose Year
Search Press Releases

Found 215 Results

September 26, 2016

Minerva Neurosciences Provides Update on MIN-101 and MIN-117 Clinical Programs

September 2, 2016

Minerva Neurosciences to Present at 23rd Annual NewsMakers in the Biotech Industry Conference on September 9, 2016

August 4, 2016

Minerva Neurosciences Reports Second Quarter 2016 Financial Results and Business Updates

July 28, 2016

Minerva Neurosciences to Report Second Quarter 2016 Financial Results and Business Updates on August 4, 2016

June 27, 2016

Minerva Neurosciences Set to Join Russell 3000® and Russell 2000® Indexes

June 14, 2016

Minerva Neurosciences Announces Pricing of Public Offering of Common Stock

June 14, 2016

Minerva Neurosciences to Present at JMP Securities Life Sciences Conference June 21, 2016

June 13, 2016

Minerva Neurosciences Announces Proposed Public Offering of Common Stock

June 1, 2016

Minerva Neurosciences to Present at Jefferies 2016 Healthcare Conference on June 8, 2016

May 26, 2016

Minerva Neurosciences Announces Positive Results From Phase IIB Trial of MIN-101 Monotherapy in Schizophrenia

«...15 161718 19...»

Investor Relations Contact

Corey Davis, Ph.D.
LifeSci Advisors, LLC
212-915-2577
cdavis@lifesciadvisors.com

Email Alerts Sign-Up

Email

I accept the Privacy Policy^*

Unsubscribe

Loading...

Minerva Neurosciences, Inc.
1500 District Avenue
Burlington, MA 01803

Company

About Us
Leadership
Board of Directors
Contact

Science

Our Approach
Pipeline
Publications
Clinical Trials

Investors

Investors Overview
News
Events
SEC Filings
Stock Information
Corporate Governance
FAQs

© 2026 Minerva Neurosciences, Inc.

Privacy Policy
Terms of Use
Accessibility Statement
Cookie Policy

Scroll to Top